UniFluVec流感疫苗载体在雪貂中对高致病性甲型流感A/印度尼西亚/5/2005(H5N1)株的保护效力
研究将UniFluVec与UniFluVec-wtNS1设计为H1N1pdm疫苗候选株,在细胞和小鼠中评估NS1与NEP修饰的减毒效果,并在雪貂中单次鼻内免疫最大可行剂量(8.7 log10 EID50)后用高致病性禽流感病毒A/印度尼西亚/5/2005(H5N1)攻击。结果显示UniFluVec具有高度减毒表型,在感染动物中实现更优的病毒清除、减少肺损伤并确保100%存活。
要点
- UniFluVec与UniFluVec-wtNS1均含异源H2N2 NEP基因作为减毒因子。
- NS1与NEP修饰独立且协同诱导温度敏感表型并增强I/II型干扰素应答。
- 雪貂单次鼻内免疫8.7 log10 EID50后攻击,UniFluVec组实现100%存活。
核心结论
- 复制缺陷型UniFluVec载体在雪貂中单次鼻内给药后显示出安全性、免疫原性及对异源高致病性禽流感病毒株的保护效力。
研究设计与样本
- 研究设计UniFluVec和UniFluVec-wtNS1为H1N1pdm疫苗候选株,在细胞和小鼠中评估NS1与NEP修饰对减毒及表型标志的影响。
- 在雪貂中单次鼻内免疫最大可行剂量(8.7 log10 EID50)后,用高致病性禽流感病毒A/印度尼西亚/5/2005(H5N1)攻击,评估安全性和预防效力。
主要发现
- NS1与NEP修饰独立且协同诱导温度敏感表型并增强I/II型干扰素应答,形成高度减毒的疫苗特征。
- UniFluVec同时携带NS基因片段中的两种修饰,在感染动物中表现出更优的病毒清除、减少肺损伤并确保100%存活。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The emergence of new influenza strains with unpredictable antigenic properties poses a significant vaccination challenge. The increasing incidence of human H5 infections underscores the urgent need for effective pre-pandemic vaccines. METHODS: The UniFluVec and UniFluVec-wtNS1 viruses were designed as H1N1pdm vaccine candidates. Both viruses contained a heterologous A/Singapore/1/57-like (H2N2) NEP gene, which served as an attenuation factor. UniFluVec additionally carried a truncated to 124 amino acids NS1 gene, and an insertion of conserved influenza sequences. UniFluVec-wtNS1 retained the wild-type NS1 gene. The impact of NS1 and NEP modifications on attenuation and phenotypic markers was assessed in cells and mice. Safety and prophylactic efficacy were assessed in ferrets following a single intranasal immunisation with the maximum feasible dose (8.7 log10 EID50), followed by challenge with the highly pathogenic avian influenza virus (HPAIV) A/Indonesia/5/2005 (H5N1). RESULTS: Modifications in NS1 and NEP independently and synergistically induced a temperature-sensitive phenotype and enhanced type I/II interferon response, resulting in a highly attenuated vaccine profile. UniFluVec, incorporating both modifications within the NS genomic segment, demonstrated superior viral clearance, reducing lung damage, and ensuring 100 % survival in infected animals. CONCLUSION: The replication-deficient UniFluVec vector demonstrates safety, immunogenicity, and protective efficacy against the heterologous HPAIV strain in ferrets following a single intranasal administration.
引用
- Romanova J, Krokhin A, Ferko B, et al. Protective efficacy of the UniFluVec influenza vaccine vector against the highly pathogenic influenza A/Indonesia/5/2005 (H5N1) strain in ferrets. Vaccine. 2025. PMID: 41046834. doi:10.1016/j.vaccine.2025.127795
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。